EZVIZ's Ongoing Smart Entry Promotion Attracts Growing Interest, Inviting More Indonesian Families to Embrace Safer and Smarter Home Living
At the heart of this campaign lies EZVIZ's vision to empower more families to enjoy the benefits of smart home security. "Smart, secure living shouldn't be reserved for a few, it should be within reach for all," said Paul Fang, Country Manager of EVIZ Indonesia. "At EZVIZ, creating safer and smarter homes starts with removing barriers and encouraging positive change at the doorstep."
Each lock in the promotional lineup features advanced unlocking technologies designed to suit different lifestyles and needs. The DL50 FVS, EZVIZ's most advanced model, uses facial recognition technology to provide fast, touch-free, and highly secure access. Similarly, the DL05 and DL06 Pro models offer the option of fingerprint unlocking, delivering quick and reliable entry with a strong focus on security. Both types of smart locks are ideal for users who value convenience and want to eliminate the hassle of keys or codes, whether for busy families, tech-savvy individuals, or professionals seeking efficient and secure home access.
For many homeowners, the DL03 and DL04 series serve as an accessible first step toward smart home security. These DIY-friendly locks support passcodes, proximity cards, and mobile app controls, making it easy to upgrade traditional doors without complex installation. This flexibility appeals to those who want to modernize their homes gradually, combining familiar unlocking options with the convenience of smart technology.
Beyond unlocking convenience, EZVIZ smart locks are built to give users complete control over home access. Through the EZVIZ app, users can assign temporary or permanent access to family members, guests, or household staff, while also receiving real-time notifications and reviewing entry history, ensuring peace of mind at all times.
With the promotion, EZVIZ continues to make advanced home security affordable and accessible, enabling more Indonesian families to enjoy smarter, safer homes. To learn more information, you can access to EZVIZ Indonesia Instagram account @ezviz.idn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710925267/en/
Contacts
Hazel Hanhanxiao16@ezviz.com
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 minutes ago
- Forbes
Holiday Season Shopping Starts In Summer As Consumers Lean On Credit
American shoppers will prioritize gifting, no matter the impact to their wallets with more than one-third (37%) believing that buying gifts for the holiday season is more important than a credit card balance this season, according to a new survey. Indeed, they are prepared to use a variety of methods to delay payment rather than cut back on the holiday season fun, with many moving into Christmas spending already in peak summer season. Travel could be the big loser if shoppers need to cut back, while many are concerned about the impact of tariffs and are getting their shopping in early to try and mitigate against future price rises. It could also be good news for discounters and those able to absorb tariff hikes, less so for branded retailers that have to pass on product increases. Austin, Texas-based Invoice Home's second annual Holiday Spending survey, conducted with third-party research firm Censuswide on the purchase intentions of 2,000 consumers, showed that a quarter of U.S. consumers plan to use controversial Buy Now, Pay Later (BNPL) services to navigate holiday spending this year, followed by employing AI to help them seek out the best prices (16%). Gen Z (20%) and Millennial (19%) respondents in particular plan to cover holiday expenses in 2025 by leveraging BNPL services. Meantime, 27% of Millennials plan to go into credit card debt (up from 21% in 2024), while 40% of Gen Z shoppers plan to dip into savings (32% last year). Consumers are also willing to delay bill payments by 2-3 weeks in the case of 26% of Gen Z and 30% Millennials, and by 1-2 months in the case of 10% of Gen Z and 16% of Millennials. Holiday Season Tariff Fears If prices continue to increase because of inflation and the impact of tariffs, Gen Z and Millennials will also consider the following to save money during the holidays. For the biggest group that means they will not travel (46% Gen Z, 30% Millennials); opt out of gifting (30% Gen Z, 27% Millennials) or thrift gifts (38% Gen Z, 26% Millennials); while a smaller number will push celebrating the holiday to 2026 when it's less expensive (16% Gen Z, 16% Millennials). Last year consumers were asked the same question – what would make someone not shop with a retailer during the holiday season. This year, trends show this is more important than ever to pay attention to. U.S. consumers will not shop with a retailer this holiday season if they see an increase in prices overall 50% (2024 -25%); an increase in cost to return 25% (11%); poor experience with a shipping carrier the retailer used 23% (11%) and poor communication from around delayed shipping 22% (10%). Holiday Season Discounting As with recent back to school surveys, it looks like consumers do want to be thrifty despite their willingness to keep on spending. If a brand/business isn't offering a discount at the time of purchase during the holidays, 42% would still feel incentivized to buy if free shipping/returns was offered, along with reward/loyalty points (34%), gift with purchase (28%) and the promise of a discount code for the next order (19%). Nearly half (47%) of respondents anticipate spending the most on holiday purchases in 2025 with Amazon, other big box retailers like Walmart, Target, etc. (32%), Black Friday/Cyber Monday (25%), and 18% with small businesses. Nearly 1 in 5 (18%) Gen Z anticipate spending the most with TikTok Shop. But despite those inter-generational differences, the holiday season appears to have started earlier than ever as low unemployment and concerns over tariff hikes motivate shoppers to put down their sunglasses and pick up their list for Santa.
Forbes
3 minutes ago
- Forbes
This REIT Is Set To Soar As Workers Return To The Office
I have to laugh when I hear the phrase 'return to the office.' I mean, COVID started more than five years ago. With the turnover in Corporate America since then, we can hardly call what's happening now a 'return.' Most of those 'returning' aren't even the same people! Nonetheless, the, shall we say, revenge, of the office is real. My wife and I saw it firsthand when we went to an open house here in Sacramento a few months ago. Staring into the front room, labeled 'home office,' my wife said, 'Programmer.' 'They're hoping for a rentback,' said the realtor. 'The couple has to move out of town for work.' Back to the Bay Area for these two! They're far from alone. Major cities—Boston, New York, San Francisco—are shaking off five years of downtown rust, preparing for commuters back four or more days a week. Funny thing is, many companies issuing back-to-office mandates these days don't have space for these workers, after shedding leases in 2021. Pinterest (PINS), you may recall, canceled a lease for nearly 490,000 square feet of future office space back then. Meta Platforms (META) walked away from 200,000 square feet in New York. Nowadays, freshly 'returned' workers are elbowing each other out of lousy temporary desks! That means we're going to be looking at a 'reverse 2021' shortly, as companies hunt for more space. And I've got a complete strategy for us to play it—and grab some high, and growing payouts, as we do. 'Revenge' of the Office Will Long Outlast Work-From-Home According to Office Index, June was the fourth-best month for in-office visits since COVID. (Placer specializes in foot-traffic data for offices, stores and the like.) That might make it sound like we're too late here. But the gap between now and the 'old times' is still wide, with office visits down about 27% compared to June 2019. A shifting trend with at least a 27% runway still ahead? That has our attention. So how do we tap into it? Here's my take on two popular office landlords. One is the wrong way to play the shift; another could work as a speculative pickup. Finally, we'll dive into our very best play on this trend, which isn't an office REIT at all. Sell This 'Revenge of the Office' REIT Yesterday Let's start with one REIT we're not going to buy: Easterly Government Properties REIT (DEA). Back in the 'old days,' having a portfolio of mainly government tenants was a plus—Uncle Sam, of course, always paid the rent! But now, a government focused REIT is the opposite of conservative. Uncle Sam has been on a spending bender and has a $2-trillion deficit to tame. That adds risk. Don't be pulled in by its 7.7% dividend. DEA's $1.6-billion of long-term debt eclipses its market cap (or value as a public company) by a lot—about $600 million. And it's been rising. DEA also executed a 1 for 2.5 reverse stock split on April 28. This is usually done to reduce its share count and give the impression of a higher share price—not a good look. Neither is the 32% dividend cut the REIT announced earlier in the month. Management still has a lot of work ahead to turn things around, and we don't need to be here for it. This NYC Office Landlord REIT Has Appeal—and Risk, Too Next up is SL Green Realty (SLG), with interests in 53 buildings, or around 31 million square feet, in New York City. SLG yields 5.1% dividend, and that payout is well-covered, at 53% of the midpoint of management's forecast funds from operations (FFO—the best metric of REIT profitability) for 2025. In fact, with that low of a ratio (for a REIT—ratios of 80%+ are common in the sector, and safe, thanks to steady rent checks), I'd expect SLG to do more on the payout front. But it's been holding off for a good reason: Management has been cutting long-term debt, from about $5.5 billion five years ago to around $3.7 billion today. That's smart, as interest rates remain elevated. But I'm concerned about the company's focus on New York, where office visits are only 5.3% below 2019, according to Placer's June numbers. Moreover, SLG's occupancy rate is a bit lower than I'd like to see, at around 91%, as of June 2025. All of this suggests SL's growth potential may be close to a top. But that's not the case with the REIT I favor most as a play on 'revenge of the office.' Our Top 'Revenge of the Office' Play Isn't an Office REIT at All There's a chance the couple whose open house I attended are headed back to the Bay Area—and renting an apartment there from Equity Residential (EQR). The REIT yields 4.1% and has interests in nearly 85,000 units in major markets like Boston, New York, Washington, DC, and, on the West Coast, Seattle, San Francisco and Southern California. Regarding those last three markets, I know there's been a lot of talk about AI replacing humans in Big Tech, and that trend will continue. But it'll still take years to play out. Meantime, Big Tech still employs more people than it did five years ago. Consider Meta, which had 58,604 workers back in 2020. As of March 31, that number stood at 76,834. And even if headcounts just held steady, demands for more in-office time alone will bring more workers back to these areas. Meta, for the record, requires three days a week, while Salesforce (CRM) now requires three days at minimum, with some teams back in their cubicles four and five days. Continued jobs growth supports EQR's cash flow—and dividend, which has returned to growth after staying flat during the pandemic years. That's notable, as management has been raising the payout straight through the current higher-rate period, which has been tough on REITs. To be sure, EQR's dividend yield is a bit low for us. But it has room to keep growing, with the current yearly amount at 70% of the midpoint of management's forecast 2025 FFO—again, low for a REIT. What's more, EQR is seeing rental rates rise, with the expectation of what it calls 'blended rates' rising around 2% to 3% this year. Occupancy is also high: 96.2% as of the end of Q2. What's more, the REIT stands to gain as interest rates move lower over time, cutting its borrowing costs. That's a big plus—and management is already doing a solid job on the debt front, reducing long-term borrowings sharply in the last decade. The current level of $7.85 billion is just 31% of EQR's market cap, or its value as a public company. That's a very light debt load for a REIT. Finally, we love the fact that EQR is smartly culling older buildings from its portfolio and using the proceeds to snap up newer ones. That, of course, boosts its portfolio value and attractiveness to tenants while going easy on its balance sheet. In the second quarter, the REIT sold off some of its older properties on the coasts and used the cash to pick up 2,064 units in fast-growing Atlanta. Management sees these new additions contributing to FFO in about two years. Tech workers, after all, love their modern conveniences. EQR's newer units give them just that—a small consolation, perhaps, for being herded back to the 9-to-5 grind. Brett Owens is Chief Investment Strategist for Contrarian Outlook. For more great income ideas, get your free copy his latest special report: How to Live off Huge Monthly Dividends (up to 8.7%) — Practically Forever. Disclosure: none
Yahoo
23 minutes ago
- Yahoo
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of the last patient last visit (LPLV) in the pivotal Phase 3 SERENITY At-Home clinical trial. Topline data from the study are expected to be released this month and are intended to support the planned supplemental New Drug Application (sNDA) to potentially expand the label of IGALMI® (dexmedetomidine) for use in the at-home (outpatient) setting. The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The SERENITY At-Home study enrolled more than 200 patients across 22 sites nationwide, with no single site enrolling more than 11% of the total patient population. Distribution of patients was balanced between the two patient populations, bipolar disorders and schizophrenia. 'This marks a major milestone in our efforts to bring a much-needed at-home (outpatient) treatment option to the millions of individuals who experience agitation related to bipolar disorders or schizophrenia,' said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. 'We're grateful to the patients, caregivers, investigators, CRO, and our internal teams who made this possible in a very timely manner. With this final visit complete, we look forward to sharing topline results soon. This is another critical step toward advancing BXCL501 (IGALMI®) as the first FDA-approved therapy for this indication in the home setting.' There are an estimated 23 million episodes of bipolar or schizophrenia-related agitation annually in the U.S. that occur at home 1-3, and there are currently no FDA-approved therapies for acute treatment in this setting. About the SERENITY At-Home Phase 3 Trial The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial is designed to evaluate 200 patients with a history of agitation episodes residing at home either alone or with caregivers/informants. Patients are self-administering 120 mcg of BXCL501 or placebo when agitation episodes occur over the 12-week trial period, with safety data (adverse events) collected during the trial. In addition, patients or caregivers/informants will complete a modified global impression of severity (mCGIs) and a clinical global impression of change (mCGI-C) two hours after dosing as an exploratory endpoint to evaluate use in the outpatient setting. About BXCL501 Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer's dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. About IGALMI® (dexmedetomidine) sublingual film INDICATION IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children. IMPORTANT SAFETY INFORMATION IGALMI can cause serious side effects, including: Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint. Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations. Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours. The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing. These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects. Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids. Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@ Please see full prescribing information at About BioXcel Therapeutics, Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit Forward-Looking Statements This current report includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this current report other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company's upcoming data release and sNDA submission. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including the factors discussed under the caption 'Risk Factors' in its most recent Quarterly Report on Form 10-Q, as such factors may be updated from time to time in its other filings with the SEC. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this current report. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this current report. Contact Information Corporate/Investors Russo Partners Nic Johnson 1.303.482.6405 Media Russo Partners David Schull 1.858.717.2310 Source: BioXcel Therapeutics, Inc. IGALMI® is a registered trademark of BioXcel Therapeutics, Inc. References Data on file relating to agitation episodes associated with schizophrenia or bipolar I or II disorder. BioXcel Therapeutics, Inc. New Haven, CT December 2020. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller. Data from Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-1540. Estimates based on whether indications are approved for at-home use for the intended patient population and such patients are treatable. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be smaller. National Institute of Mental Health. Prevalence of bipolar disorder in adults. November 2017. Accessed December 16, 2022. Episode estimations may not reflect potential treatable episodes, and actual addressable market may be in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
